Kim Hong-tae, CEO of ImmunOnsia, and Park Eun-young, CEO of AINB (second and third from the left in the photo), are posing for a commemorative photo at the business agreement signing ceremony. Photo by ImmunOnsia
ImmunOnsia announced on the 13th that it has signed a comprehensive memorandum of understanding (MOU) with AINB, an AI antibody discovery and development biotech, for the discovery and development of new candidate substances.
Through this agreement, both companies plan to jointly conduct research and promote mutual exchange in the discovery of new candidate substances and experimental verification processes by utilizing AINB's AI-based antibody discovery technology and ImmunOnsia's immune-oncology antibody development technology. AINB is conducting data-driven antibody drug candidate discovery based on its proprietary AI technology.
Kim Hong-tae, CEO of ImmunOnsia, said, "We aim to use a new paradigm, an AI-based novel antibody screening platform, to quickly and cost-effectively discover new targets and expand our immune-oncology drug pipeline."
Park Eun-young, CEO of AINB, also stated, "Through collaboration with ImmunOnsia, which has high expertise in the immune-oncology field, we will strive to discover numerous promising next-generation immune-oncology antibodies."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
